Ruben Rhoades

Dr. Ruben Rhoades

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
RRRuben Rhoades
Ruben Rhoades
ZFZachary French
Zachary French
AYAmy Yang
Amy Yang
KWKaren Walsh
Karen Walsh
DDDouglass A. Drelich
Douglass A. Drelich
SMSteven McKenzie
Steven McKenzie
Persons with bleeding disorders (PwBD) are at high risk for bleeding with invasive procedures. However, the risk of bleeding in PwBD undergoing major surgery and outcomes of patients managed perioperatively at a hemophilia treatment center (HTC) are not well described. We performed a retrospective review of surgical outcomes among PwBD undergoing major surgery between January 1st, 2017 and December 31st, 2019 at the Cardeza Foundation Hemophilia and Thrombosis Center in Philadelphia, PA. The primary outcome was postoperative bleeding, assessed according to the ISTH-SSC's 2010 definition. Secondary outcomes included use of unplanned postoperative hemostatic therapy, LOS, and 30-day readmission rate. Results were compared to non-PwBD population from a surgical database, matched for surgery, age, and sex. During the study period, 50 PwBD underwent 63 major surgeries. The most common diagnoses were VWD (64%) and hemophilia A (20.0%). The most common surgical procedure category was orthopedic (33.3%), predominantly arthroplasties. Postoperatively,4.8% of procedures were complicated by major bleeding and 1.6% by non-major bleeding. The mean LOS was 1.65 days, and 30-day readmission rate was 1.6%. In comparison to matched, non-PwBD patients in a national surgical database undergoing the same procedures, study patients had a similar rate of bleeding complications per procedure (5.0% vs 1.04% P = .071, Fisher's exact test). PwBD undergoing major surgeries have low rates of major bleeding when receiving comprehensive care at an HTC. Bleeding and hospital readmission rates were similar to non-PwBD baseline in a large database.

1 July 2021 in Thrombosis Research
Verified
Journal Article
Closed access
RRRuben Rhoades
Ruben Rhoades
RLRon Leong
Ron Leong
JKJason Kopenitz
Jason Kopenitz
BTBrandi Thoma
Brandi Thoma
LMLydia McDermott
Lydia McDermott
NANawar Al-Rawas
Nawar Al-Rawas

17 October 2017 in Biomedicines
Verified
Journal Article
Open access
PDF file
RRRuben Rhoades
Ruben Rhoades
SGSameh Gaballa
Sameh Gaballa
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality following allogeneic stem cell transplantation. Current therapies, including corticosteroids and calcineurin inhibitors, are only effective in roughly 50% of cases; therefore, new treatment strategies are under investigation. What was previously felt to be a T cell disease has more recently been shown to involve activation of both T and B cells, as well as a number of cytokines. With a better understanding of its pathophysiology have come more expansive preclinical and clinical trials, many focused on B cell signaling. This report briefly reviews our current understanding of cGVHD pathophysiology and reviews clinical and preclinical trials with B cell-targeted agents.

24 August 2023 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
SMShyam Majmundar
Shyam Majmundar
STSameep Thapa
Sameep Thapa
EMElan S. Miller
Elan S. Miller
RBRodney Bell
Rodney Bell
RDRobin Dharia
Robin Dharia
RRRuben Rhoades
Ruben Rhoades

14 March 2019 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
RRRuben Rhoades
Ruben Rhoades
JGJerald Gong
Jerald Gong
NPNeil Palmisiano
Neil Palmisiano
OAOnder Alpdogan
Onder Alpdogan
Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B-cell lymphoma, highly associated with HIV and Epstein-Barr virus (EBV) infections. It commonly presents in extranodal sites, often an oral mass, but reports of primary central nervous system PBL (PCNSPBL) are exceedingly rare. Here, we report on a 33-year-old man with newly diagnosed HIV infection who presented with acute-onset unilateral visual disturbance and was found to have biopsy-proven PCNSPBL. The neoplastic cells displayed a plasmacytoid appearance, with the expression of CD38 and CD138, and were positive for EBV by in situ hybridisation for EBV-encoded RNA. Systemic workup revealed the presence of Kaposi sarcoma, but no evidence of lymphoma. He is currently being treated with high-dose methotrexate, as well as antiretroviral therapy for his HIV infection, and has achieved a complete response.

5 October 2025 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Open access
PDF file
EMEliakim Munda
Eliakim Munda
RRRuben Rhoades
Ruben Rhoades
Hereditary thrombophilia testing is frequently ordered after venous thromboembolism (VTE), despite little evidence of clinical utility and most guidelines cautioning against testing. We conducted a retrospective, observational study of inpatient hereditary thrombophilia testing ordered during a hospital admission for acute VTE between 2019 and 2024. We aimed to characterize patterns of testing results, and costs, and to evaluate whether younger patients and those with unprovoked VTE were more likely to test positive for hereditary thrombophilia. A total of 835 hereditary thrombophilia tests – including those for factor V Leiden, prothrombin G20210A , deficiencies of protein S, protein C, and antithrombin, hyperhomocysteinemia, and plasminogen activator inhibitor-1 excess – were ordered in 220 patients. Overall, 19.6% of results were abnormal, and 45.0% of patients had at least one abnormal result. There was no difference in the rate of positive results among patients with provoked vs. unprovoked VTE (30.7% vs. 34.5%, p = .554) nor patients < 50 vs. ≥ 50 years of age (33.1% vs. 32.4%, p = .912). Only 4/99 (4.0%) patients with an abnormal result had their clinical management clearly changed due to the result. The tests totaled $385,161 USD in institutional charges and $26,029 USD in Medicare fees. Inpatient hereditary thrombophilia testing during admission for acute VTE is low yield, with frequent abnormal results, many of which likely represented false positives, and minimal impact on clinical management with high costs. Graphical abstract